Giant Puffball

Metadata

Regulatory Status

China (Chinese Pharmacopoeia)

• Listed: Yes. Ma Bo (马勃) is an official drug in the Chinese Pharmacopoeia (2020 edition).
• Important note on species: The pharmacopoeia entry for Ma Bo encompasses several puffball species used interchangeably: Calvatia gigantea, Calvatia lilacina (syn. Handkea utriformis), and Lasiosphaera fenzlii. These species are considered functionally equivalent in TCM for the Ma Bo indication, though their precise chemical profiles differ.
• Traditional indications (TCM): Clearing heat from the lungs, relieving sore throat, stopping bleeding. Used for acute pharyngitis, laryngitis, epistaxis (nosebleed), and traumatic hemorrhage.
• TCM properties: Pungent in flavor, neutral in nature. Enters the Lung meridian. The dried mature spore mass is applied topically as a hemostatic powder or decocted internally for pharyngeal inflammation.
• Dosage form in TCM: Mature specimens (brown spore mass) are dried and used as a hemostatic powder for topical application; immature specimens (white flesh) are sliced and dried for internal decoction.

United States

• FDA GRAS Status: Not established. Calvatia gigantea is consumed as food (edible when immature) but has no formal GRAS determination.
• Dietary Supplement: Not marketed as a dietary supplement. No NDI notification filed.
• Historical NCI involvement: Calvacin was investigated under the NCI natural products screening program (NSC-47693) in the 1960s-70s but was never approved as a pharmaceutical.

European Union

• Novel Food Status: Not specifically authorized under Regulation (EU) 2015/2283, though the species is consumed as food in parts of Europe.
• Traditional use: Consumed as an edible mushroom in European culinary tradition when young and white, but no established European herbal medicine tradition.

Japan

• Not listed in the Japanese Pharmacopoeia. No Kampo or traditional Japanese medicine use.

Conditions & Indications

Primary Indications (Traditional Use / Historical)

• Hemostasis (topical, TCM): The dried spore powder of Ma Bo has been used in TCM for centuries as a topical hemostatic agent for epistaxis (nosebleed), wound bleeding, and gingival hemorrhage. The mechanism is attributed to the physical absorbent properties of the fine spore powder and the astringent action of calvatic acid and other phenolic compounds. This is the most established and continuously practiced indication.
• Pharyngitis and laryngitis (TCM): Internal decoction of Ma Bo is a traditional treatment for acute sore throat, hoarseness, and pharyngeal inflammation. TCM classifies this as “clearing heat from the lungs and relieving the throat.” Some modern Chinese clinical observations (non-controlled) report benefit in acute pharyngitis.

Secondary Indications (Historical Research)

• Anti-tumor activity (calvacin — abandoned): Calvacin, a mucoprotein fraction isolated from Calvatia gigantea, was one of the earliest fungal compounds investigated for anti-cancer activity by the NCI. Roland et al. (1960) first reported anti-tumor activity against sarcoma 180 in mice. Subsequent NCI-sponsored research through the 1960s and early 1970s confirmed activity against multiple transplantable animal tumor models (sarcoma 180, Ehrlich carcinoma, Walker 256 carcinosarcoma). However, Phase I/II clinical evaluation was terminated due to unacceptable toxicity including anaphylactic reactions and coagulopathy (disseminated intravascular coagulation-like syndrome). The calvacin program represents an important historical case study in the challenges of translating potent in vitro/animal anti-cancer activity to safe human therapeutics. This failure predated and likely informed the more cautious development approach later taken with mushroom-derived immunomodulators such as PSK from turkey tail.

Emerging/Preclinical Indications

• Antimicrobial activity: Calvatic acid, an antibiotic compound isolated from C. gigantea, demonstrates broad-spectrum antibacterial activity against Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis) and moderate antifungal activity. This compound has not been developed as a pharmaceutical.
• Polysaccharide immunomodulation: Polysaccharides extracted from C. gigantea fruiting bodies demonstrate macrophage activation and splenocyte proliferation in vitro, consistent with general medicinal mushroom polysaccharide activity. This activity has not been characterized as extensively as for the primary immunomodulatory mushrooms.
• Anti-inflammatory activity: Crude extracts of C. gigantea demonstrate modest anti-inflammatory activity in carrageenan-induced paw edema models in rats, potentially supporting the traditional TCM pharyngeal anti-inflammatory indication. Limited research.

Mechanism of Action

Primary Mechanisms

1. Calvacin Anti-tumor Activity (Historical) Calvacin is a high-molecular-weight mucoprotein (glycoprotein) isolated from the immature fruiting body of Calvatia gigantea. The compound demonstrated potent anti-tumor activity in multiple animal transplantable tumor models, inhibiting tumor growth by 80-100% against sarcoma 180 in mice at intraperitoneal doses of 5-20 mg/kg. The mechanism of action was never fully elucidated but was attributed to a combination of direct cytotoxicity and immune-mediated anti-tumor activity. Calvacin induced hemorrhagic necrosis within tumor tissue, suggesting a vascular disruption component. However, the same mechanism that caused tumor vascular damage also affected normal vasculature at therapeutic doses, producing the coagulopathy and anaphylactoid reactions that terminated clinical development. Calvacin’s failure illustrates the critical distinction between tumor-selective and non-selective cytotoxic mechanisms — the compound lacked sufficient therapeutic index for safe human use.

2. Hemostatic Activity (TCM Topical Use) The hemostatic action of Ma Bo spore powder involves both physical and biochemical mechanisms. The extremely fine, hydrophobic spore particles (3-5 micrometers) provide a large surface area that promotes platelet aggregation and fibrin network formation when applied to wound surfaces. Calvatic acid and phenolic compounds provide mild astringent activity that constricts superficial blood vessels. This dual physical-biochemical hemostatic mechanism is well-suited to the topical application described in TCM for epistaxis and minor wound bleeding.

3. Anti-inflammatory Pharyngeal Activity The traditional use for sore throat is attributed to anti-inflammatory effects of polysaccharides and phenolic compounds that reduce pharyngeal mucosal edema and suppress local inflammatory mediator production. The “heat-clearing” TCM classification aligns with an anti-inflammatory mechanism, though the specific molecular targets have not been characterized in modern pharmacological studies.

Secondary Mechanisms

4. Calvatic Acid Antimicrobial Activity Calvatic acid (L-2-amino-4-pentynoic acid) is a non-proteinogenic amino acid antibiotic that inhibits bacterial cell wall synthesis and protein synthesis. The compound demonstrates bactericidal activity against Gram-positive organisms at concentrations comparable to conventional antibiotics in vitro, but has not been developed due to limited spectrum and unknown human pharmacokinetics.

5. Polysaccharide Immunomodulation Crude polysaccharide fractions from C. gigantea activate macrophages and enhance phagocytic activity through pattern recognition receptor signaling, consistent with the general beta-glucan immunomodulatory mechanism shared across medicinal mushrooms. This activity is not well characterized for C. gigantea specifically and is likely less potent than the polysaccharide immunomodulation of dedicated immunomodulatory species (turkey tail, reishi, maitake).

Clinical Evidence Summary

There are no modern clinical trials evaluating Calvatia gigantea in human subjects. The evidence base consists of historical NCI anti-tumor research (1960s-70s), TCM traditional use documentation, and limited modern preclinical studies.

Historical Calvacin Research (NCI)

TCM Clinical Observations (Non-Controlled)

Chinese-language literature contains clinical observations of Ma Bo use for acute pharyngitis and epistaxis, but these are case series and clinical experience reports rather than controlled trials. No randomized controlled trial of Ma Bo for any indication has been published.

Modern Preclinical Studies

Evidence Limitations

• No modern clinical trials of any design have been published for Calvatia gigantea.
• The most significant body of evidence (calvacin anti-tumor research) is historical (1960s-70s) and resulted in program termination due to unacceptable toxicity. This evidence demonstrates that calvacin is not a viable therapeutic agent, which is itself a clinically important finding.
• TCM evidence for Ma Bo consists of traditional use documentation and uncontrolled clinical observations, not randomized trials.
• Modern preclinical research is extremely limited in volume. C. gigantea receives far less research attention than other medicinal mushrooms.
• The TCM drug Ma Bo encompasses multiple puffball species; clinical observations attributed to Ma Bo may not reflect C. gigantea specifically.
• The species produces fruiting bodies seasonally and unpredictably, making standardized research material difficult to obtain. No commercial cultivation system exists for C. gigantea.
• The calvacin toxicity findings mean that the most potent characterized bioactive from this species is unsuitable for human use, leaving only the modest polysaccharide immunomodulatory and traditional hemostatic/anti-inflammatory activities as viable therapeutic directions.

Safety Profile

General Assessment

Calvatia gigantea has a long history of consumption as an edible mushroom in Europe and Asia when harvested immature (white, firm flesh). As a food, it is considered safe and palatable. However, the safety profile of concentrated medicinal preparations is poorly characterized, and the calvacin anti-tumor fraction has demonstrated significant toxicity in clinical settings.

Contraindications

• Pregnancy and lactation: No safety data for medicinal preparations. The species is consumed as food in pregnancy in some cultures, but concentrated extracts or medicinal doses lack safety evaluation.
• Known mushroom allergy: Individuals with allergies to Agaricaceae mushrooms should avoid use.
• Spore inhalation (lycoperdonosis): Inhalation of large quantities of puffball spores from mature specimens can cause lycoperdonosis, a granulomatous pneumonitis. This rare condition has been documented in case reports, typically from deliberate deep inhalation of puffball spores (sometimes as folk medicine for epistaxis) or occupational exposure. Mature, spore-producing specimens should be handled with respiratory precaution.
• Calvacin-containing preparations at high doses: Based on the NCI experience, concentrated calvacin fractions are toxic and should not be used. This contraindication applies to calvacin-enriched extracts, not to crude fruiting body preparations or food-grade mushroom products.

Drug Interactions

No drug interactions have been documented. Given the extremely limited pharmacological characterization, no theoretical interactions can be confidently predicted. The traditional topical hemostatic use suggests mild pro-coagulant activity when applied to wounds, but systemic effects from oral consumption of food-quantity mushroom are not expected.

Adverse Effects

• As food (immature fruiting body): Generally well-tolerated. No adverse effects reported from culinary consumption of properly identified, immature C. gigantea.
• Calvacin (historical pharmaceutical use): Anaphylactic/anaphylactoid reactions and coagulopathy (DIC-like syndrome) were observed in NCI clinical studies at therapeutic anti-tumor doses. These effects are specific to concentrated calvacin fractions at high doses and are not expected from crude mushroom preparations.
• Lycoperdonosis: Granulomatous pneumonitis from spore inhalation is a rare but documented adverse effect of handling mature puffball specimens. Symptoms include cough, dyspnea, and fever developing days to weeks after exposure. Treatment is supportive and may include corticosteroids.
• Misidentification risk: Immature puffballs can resemble immature specimens of highly toxic species, particularly Amanita (death cap) “button” stage. All puffball specimens should be sliced in half before consumption to confirm homogeneous white interior flesh without any internal gill structure or developing cap.

Toxicology

• Crude C. gigantea fruiting body has no reported acute toxicity when consumed as food.
• Calvacin toxicity: The calvacin fraction demonstrated a narrow therapeutic index in animal models and unacceptable toxicity in human clinical trials. The LD50 for purified calvacin in mice was approximately 40 mg/kg IP, with anti-tumor doses of 5-20 mg/kg — a narrow 2-8x safety margin insufficient for clinical use.
• No formal toxicological evaluation (subchronic, genotoxicity) has been published for crude C. gigantea preparations.

Clinical Dosage

TCM Dosage (Ma Bo)

• Internal decoction: 3-6 g/day of dried Ma Bo (mature or immature fruiting body), decocted in water
• Topical hemostatic powder: Dried mature spore mass applied directly to bleeding wounds or packed into nostrils for epistaxis
• Note: TCM dosing applies to crude drug preparations used within the traditional framework. Ma Bo may include C. gigantea, C. lilacina, or L. fenzlii interchangeably.

Culinary Use (Food)

• Immature fruiting bodies with firm, white flesh are sliced and cooked (pan-fried, breaded, or added to soups). This is a food use, not a medicinal dose, and no therapeutic claims are made.

No Modern Standardized Dosage

• No clinical trials have established therapeutic doses for any modern indication.
• Calvacin is not a viable therapeutic agent due to toxicity and no dosing recommendations are made.
• Polysaccharide extracts from C. gigantea have not been evaluated in human dosing studies.

Product Quality Considerations

• Seasonal availability: Calvatia gigantea fruits unpredictably in late summer to autumn and cannot be cultivated commercially. Supply is entirely from wild harvest, making standardized product development impractical.
• Species identification: Correct identification is essential. Immature puffballs must be distinguished from immature Amanita species (which can be lethal) by cutting specimens in half to confirm homogeneous white flesh without any internal structure.
• Maturity stage: For internal medicinal use, only immature specimens with completely white, firm, homogeneous flesh should be used. Specimens showing any yellowing, browning, or spore development are past their optimal stage for internal consumption.
• Standardization: No product standardization exists. Polysaccharide content, calvacin content, and calvatic acid content are not routinely analyzed in any commercial context.

Sources

• Roland JF, Chmielewski MA, Grossi AV. Calvacin: a new antitumor agent. Science. 1960;132(3425):544
• Gruber L, Korn G, Roland JF. Antitumor activity of calvacin and related compounds. Proc Soc Exp Biol Med. 1963;114:524-528
• Hartwell JL. Plants used against cancer: a survey. Lloydia. 1971;34(4):386-425
• Lam YW, Ng TB, Wang HX. Antiproliferative and antimitogenic activities in a peptide from puffball mushroom Calvatia caelata. Biochem Biophys Res Commun. 2001;289(3):744-749
• De Silva DD, Rapior S, Sudarman E, et al. Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry. Fungal Divers. 2013;62:1-40
• Petrovic J, Stojkovic D, Reis FS, et al. Study on chemical, bioactive and food preserving properties of Laetiporus sulphureus and Calvatia gigantea. Food Funct. 2014;5(7):1441-1451
• State Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Vol 1. 2020 Edition
• Cochrane JC, Cochrane CG, Gruber JA. Calvacin: isolation, characterization and mechanism of action. In: Symposium on Pharmacologically Active Substances of Microbial Origin. Academic Press; 1971:95-112
• Suay I, Arenal F, Asensio FJ, et al. Screening of basidiomycetes for antimicrobial activities. Antonie Van Leeuwenhoek. 2000;78(2):129-139
• Munro DB, Steben RE. Lycoperdonosis: a review. Clin Toxicol. 1989;27(1-2):5-13
• Beneke ES, Rogers AL, eds. Medical Mycology and Human Mycoses. Star Publishing; 1996
• Ying J, Mao X, Ma Q, Zong Y, Wen H. Icons of Medicinal Fungi from China. Science Press, Beijing; 1987

Connections

• Agaricus blazei — Both belong to the family Agaricaceae, though their medicinal profiles differ substantially. Agaricus blazei (Royal Sun Mushroom) has a much more developed evidence base for polysaccharide immunomodulation and has been evaluated in clinical trials, while C. gigantea remains at the historical and preclinical stage. The contrast illustrates how different Agaricaceae species have followed divergent paths in medicinal mushroom research.
• Turkey Tail — Turkey tail’s PSK (polysaccharide-K) represents the successful pharmaceutical development pathway that calvacin from C. gigantea failed to achieve. PSK demonstrated sufficient safety and efficacy to earn regulatory approval in Japan as a cancer adjunctive therapy — a success that contrasts directly with calvacin’s abandonment due to unacceptable toxicity. The comparison of these two fungal anti-cancer research programs illustrates the critical role of therapeutic index in drug development: turkey tail’s polysaccharide immunomodulators work by enhancing the host immune response (indirect, well-tolerated), while calvacin’s direct cytotoxic mechanism lacked tumor selectivity (direct, toxic).
• The historical calvacin story represents an important case study in mycotherapy: the transition from potent but toxic direct anti-tumor compounds (calvacin, 1960s-70s) to safer immunomodulatory polysaccharide approaches (PSK from turkey tail, lentinan from shiitake, beta-glucan from maitake, 1980s-present) reflects a fundamental shift in the strategic approach to fungal anti-cancer drug development. Giant Puffball’s calvacin failure arguably contributed to the pharmacological rationale that later guided successful mushroom pharmaceutical development.
• Calvatia gigantea occupies a unique ecological and morphological niche among medicinal fungi as the largest fruiting species, a grassland saprotroph (most medicinal mushrooms are wood-decay or mycorrhizal species), and the source of one of the first fungal anti-cancer compounds to reach human clinical evaluation — even though that evaluation ultimately failed. Its TCM identity as Ma Bo (shared with related puffball species) provides a traditional use framework that remains active in Chinese clinical practice, primarily for hemostatic and pharyngeal indications that are modest compared to the anti-tumor aspirations of the calvacin era.